WHO says mpox cases in Congo's epicenter where the new variant was detected may be 'plateauing'
The World Health Organization says mpox cases in the region of Congo where a new and more infectious variant was first detected appear to be “plateauing,” even as the virus continues to increase in other regions of the country,
Kivu Bioscience Raises $92 Million Series A Led by Novo Holdings to Advance Next-Generation Antibody-Drug Conjugates ...
Congolese radio journalist Yoshua Kambere Machozi was arrested by members of the rebel group M23 (23 March Movement) on 29 ...
Rwanda and the Democratic Republic of Congo (DRC) launched a joint monitoring mechanism in a bid to tame a vicious cycle of ...
Daily Maverick on MSN1d
Return to Rwanda — a journey beyond the pastRwanda offers a fresh perspective for travellers, blending its natural beauty with a sense of community. From the shores of ...
Kamandi-Gite is situated approximately 130 kilometres from Goma City. Several reliable sources confirmed the presence of M23 ...
Some health officials say mpox cases in Congo appear to be “stabilizing.” It's a possible sign that the epidemic for which ...
San Francisco, USA-based biotech start-up Kivu Bioscience has announced the closing of a $92 million Series A financing round ...
The World Health Organization reports that mpox cases are plateauing in Congo's South Kivu region, despite rising numbers in the rest of the country, Burundi, and Uganda. With fewer than 100 confirmed ...
Kivu Bioscience是一家癌症靶向药物研发商，该公司专有的linker-payload技术可提供更高的安全性和有效性，最大限度地减少脱靶效应，从而改善患者预后。近日，Kivu Bioscience宣布完成9200万美元A轮融资，由Novo Holdings领投，Gimv、Red Tree Venture ...
GIMV NV (GB:0EKR) has released an update. Gimv has participated in a $92 million Series A funding round for Kivu Bioscience, aiming to advance next-generation antibody-drug conjugates (ADCs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback